Abranilla, Baby Girl .
HRN: 26-63-00 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/30/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/30/2025
02/06/2025
IV
9 Mg
Q 24
PSNB
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes